Investors & Media


Oncternal Therapeutics is a privately-held oncology company with a pipeline of exciting new cancer therapeutics.

With support from our angel investors and other funding sources, we have formed a world-class oncology company focused on targets that are uniquely expressed within cancer cells.

Our highly experienced leadership team has significant discovery, development and commercial experience. Together, our founders have started or developed almost 30 successful biotechnology companies. We also have the experience and expertise to oversee multiple development programs, capitalizing on their synergies in a capital efficient manner.

Oncternal Therapeutics continues to seek funding to support advancement of our pipeline across multiple tumors. If you are a member of the press or investment community and would like to learn more about these opportunities:

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers by focusing on targets that are differentially expressed by cancer cells. The company is leveraging its scientific and development expertise, as well as academic collaborations, to rapidly advance its two pipeline products, cirmtuzumab, an anti-ROR1 monoclonal antibody, and TK216, a small molecule that inhibits the biological activity of ets-family transcription factor oncoproteins. In a collaboration with UC San Diego, Oncternal is developing a chimeric antigen receptor expressing T cell (CAR-T) targeting ROR1.

Investor Contact

James Breitmeyer
Oncternal Therapeutics
T: 858-434-1113

Media Contact

Kelly Conlon
First Light Communications
T: 207-233-2430